– USA, WA – Nativis Inc., a clinical-stage bio-electronics company developing non-invasive treatments for cancers and other serious diseases, today announced the appointment of Dr. Daniel Kisner to the company’s board of directors, effective immediately.
Kisner is an independent pharmaceutical consultant and 30-year veteran of the pharmaceutical and medical device industries with extensive experience at both public and private health care companies. His most recent operating position was president and CEO of Caliper Technologies, a leader in microfluidic lab-on-a-chip technology, where he led the company’s development from early stage to a publicly traded commercial organization with two acquisitions.
Prior to Caliper, Kisner was president and chief operating officer of Isis Pharmaceuticals (now Ionis Pharmaceuticals) from 1991-1999. He also held the positions of divisional vice president of pharmaceutical development at Abbott Laboratories and vice president of clinical research & development at SmithKline Beckman. Board certified in internal medicine and medical oncology, he has held a tenured position in the Division of Oncology at the University of Texas School of Medicine at San Antonio. Kisner obtained his bachelor’s degree from Rutgers University and his medical degree from Georgetown University.
More recently, Kisner has also been a partner of Aberdare Ventures, investing in early-stage biotech companies. He has served as chairman of the boards of Tekmira Pharmaceuticals, Avera Pharmaceuticals, Kemia and Sequoia Pharmaceuticals as well as Caliper at different stages in his career. He now holds a seat on the boards of directors of Zynerba Pharmaceuticals, Conatus Pharmaceuticals and Dynavax Technologies.
“We would like to welcome Dr. Kisner to our board of directors and look forward to his contributions,” said Nativis CEO Chris Rivera. “Dan’s extensive background in the health care industry from a public and private company executive perspective, in conjunction with his medical background and diverse corporate roles, will prove invaluable as we navigate the company’s expansion and future growth.”
Kisner added, “I am pleased to be joining the board of Nativis as they push towards a breakthrough with the Nativis Voyager® system to battle glioblastoma and other cancers. I look forward to using my experience in drug development and the pharmaceutical industry to advance their proprietary ulRFE™ technology. I am also excited to work with the industry leaders that have joined the board to help guide the company to further success.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, Washington, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.
For more information : http://www.nativis.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.